Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
2023年10月27日 - 9:00PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
that it will present positive preliminary data from the phase 1
dose escalation portion of the ongoing phase 1/2 KB-0742 study at
the Connective Tissue Oncology Society annual meeting being held
November 1-4, 2023, in Dublin, Ireland. The presentation will
include clinical data that was first presented at the
AACR-NCI-EORTC International Conference on October 13, 2023, in
Boston, Mass in the context of pre-clinical models that provide a
better understanding of the observed anti-tumor activity.
Oral Presentation
information
Session Title: Session 4:
Medical and Pediatric Oncology and Trials
Presentation Title: A first
in-human study of CDK9 inhibitor KB-0742 demonstrates preliminary
evidence of clinical activity in transcriptionally addicted
sarcomas
Presenter: Brian Van Tine,
M.D., of Washington University School of Medicine in St. Louis
Abstract #: 1569811
Date and Time: Thursday
November 2, 2023, from 4:00 PM - 5:30 PM IST
To read the press release on the data presented
at the AACR-NCI-EORTC International Conference in Boston, Mass. you
may visit https://ir.kronosbio.com/news-releases
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that
is advancing two investigational compounds in clinical trials for
patients with cancer. The company is developing the CDK9 inhibitor
KB-0742 as a treatment for MYC-amplified solid tumors and other
transcriptionally addicted solid tumors and lanraplenib, a
next-generation SYK inhibitor, for patients with FLT3-mutated acute
myeloid leukemia. The company’s scientific focus is on developing
medicines that target the deregulated transcription that is the
hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and
has a research facility in Cambridge, Mass. For more information,
visit www.kronosbio.com or follow the company on LinkedIn.
Company Contact:Sarah Connors,
Vice President of Investor Relations and Corporate
CommunicationsKronos
Bio857-290-7305sconnors@kronosbio.com
Agency Contact:Brendan Strong,
Managing DirectorArgot Partners
212-600-1902kronosbio@argotpartners.com
Kronos Bio (NASDAQ:KRON)
過去 株価チャート
から 4 2024 まで 5 2024
Kronos Bio (NASDAQ:KRON)
過去 株価チャート
から 5 2023 まで 5 2024